Dr. Robert F. See, MD

Dr. See practices at California Retina Consultants, a Professional Medical Corporation in Santa Barbara, California.

Dr. See's NPI, 1407955073, was assigned on September 21, 2006. Dr. See graduated from University of Toledo College of Medicine and Life Sciences in 1997. Dr. See holds California license A76099.

Dr. See's primary practice is California Retina Consultants, a Professional Medical Corporation, at 525 E Micheltorena St, Santa Barbara, CA 93103 in Santa Barbara County. The practice phone is (805) 963-1648.

Dr. See's primary practice is California Retina Consultants, a Professional Medical Corporation in Santa Barbara, California. Dmand AI also links Dr. See to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. See practices. Vendor and product names are available with a free account.

Retina specialist is Dr. See's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dmand AI has Dr. See's licenses on file in 4 states: California, North Carolina, New Jersey and Pennsylvania.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. See treats.

CMS data shows 20,425 Medicare services from Dr. See across 21 procedure codes in 2024, for 816 Medicare patients. Medicare paid $1,019,716 for them. Every service was in an office.

CMS counts 816 Medicare patients who saw Dr. See in 2024. The largest group is 65 to 74, with 321 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. See's median patient age at 68, with 52% women.

In 2024, Dr. See wrote 652 Medicare Part D claims for 182 patients. 66% of them were for generic drugs. CMS names the drug for 557 of them, across 13 drugs with 11 or more claims each, at $17,181 in total drug cost. In 2023, CMS named 1,188 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. See for performance year 2024, reported as part of a group.

Dmand AI links 8 papers to Dr. See, published from 2014 to 2017. The most frequent topics are Intravitreal Injections, Visual Acuity and Angiogenesis Inhibitors. Dr. See has published most often in Retina. Dr. See's most frequent co-authors are Robert Logan Avery, MD, Alessandro Attilio Castellarin, MD and Dante J. Pieramici, MD.

CMS Open Payments shows 144 general payments to Dr. See from 17 drug and device companies from 2016 to 2025. Gifts make up the largest share, 56% of the total. Carl Zeiss Meditec, Inc. paid the most, $5,177.

Dr. See graduated from University of Toledo College of Medicine and Life Sciences in 1997.

Dr. See is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.